As major health systems accuse CVS Health of diverting hundreds of millions of dollars in 340B savings, the litigation highlights a broader challenge for hospital CFOs.
KEY TAKEAWAYS
Increasingly, 340B savings help offset Medicaid shortfalls and fund mission-driven services that operate at negative margins.
CFOs should evaluate whether existing PBM, specialty-pharmacy and contract-pharmacy agreements provide sufficient audit rights and data access.
Future financial risk may stem less from claims denials and more from opaque reimbursement methodologies, spread-pricing allegations and contract-performance issues embedded in complex pharmacy arrangements.
Three major health systems—including affiliates of the University of Michigan, Mount Sinai and the University of Kansas—have individually launched lawsuits against CVS Health alleging that the company and its subsidiaries diverted approximately $250 million in 340B drug-program savings through reimbursement practices that improperly retained funds intended for safety-net providers. The cases claim the alleged practices occurred between 2020 and 2025 and involved what plaintiffs describe as a concealed pricing arrangement that redirected 340B revenue away from hospitals.
However, the significance goes well beyond the courtroom.
The litigation underscores how dependent many health systems have become on supplemental revenue sources to offset chronic Medicaid underpayment and rising uncompensated care costs. The lawsuits arrive at a time when hospital margins remain fragile despite some post-pandemic stabilization, and when many organizations are increasingly reliant on pharmacy operations to support broader community-benefit and clinical programs.
A spokesperson for Mount Sinai commented:
“Several health care systems across the country, including Mount Sinai, have brought this lawsuit to ensure that the funds that are supposed to be available to mission-driven hospitals like Mount Sinai that serve a disproportionate share of the Medicaid and uninsured population, are not wrongly skimmed off by for profit intermediaries.”
According to the complaints, the hospitals estimate they lost more than half of the 340B savings they should have received during the period in question. One University of Michigan-related lawsuit alone alleges more than $66 million in lost revenue.
This lawsuit highlights that pharmacy revenue has shifted into a deep finance issue.
Historically, 340B was seen as a beneficial and fairly stable funding mechanism, but with the program sitting at the center of disputes involving manufacturers, pharmacy benefit managers (PBMs), contract pharmacies and regulators, are the complications outweighing its worth? The CVS litigation highlights the growing complexity of revenue flows within vertically integrated healthcare organizations, where PBMs, specialty pharmacies and insurers may all participate in a single transaction.
With hospitals already grappling with Medicaid reimbursement rates that often fail to cover the cost of care, any disruption in 340B revenue can create disproportional financial consequences. Since many systems use 340B-generated savings to subsidize behavioral health programs, oncology services, rural outreach, and care for uninsured populations. A material reduction in those funds can quickly translate into operating-budget pressure.
The lawsuits also reveal that CFOs are increasingly scrutinizing third-party contracts for revenue leakage. Several of the complaints allege that hospitals struggled to obtain underlying data needed to audit transactions and verify reimbursement methodologies. The plaintiffs claim requests for transparency and audits were resisted, limiting their ability to independently validate payment calculations.
That issue should resonate across the industry.
As payer-provider relationships become more complex, CFOs may need to devote greater resources to contract analytics, pharmacy revenue-cycle oversight, and independent auditing capabilities. Revenue integrity programs that traditionally focused on claims and denials management may need to expand deeper into 340B administration, PBM contracts, and specialty-pharmacy arrangements.
Whether the hospitals ultimately prevail remains uncertain. CVS has not publicly conceded the allegations, and the claims will be tested through litigation. But the cases reinforce a reality many CFOs already recognize: in an era of Medicaid pressure and thin operating margins, protecting every dollar of supplemental revenue has become crucial.
HENRY KOTULA 